Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

About this update from Foghorn Therapeutics Inc.

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control ® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. B. Riley Securities Precision Oncology and Radiopharma Conference TD Cowen 45th Annual Health Care Conference A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website,  www.foghorntx.com , and will be available for 90 days. About Foghorn Therapeutics Foghorn ® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control ® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn . Contact: Karin Hellsvik, Foghorn Therapeutics Inc. [email protected]

View stock analysis, news, and events for Foghorn Therapeutics Inc.